Dose coefficients of radiopharmaceuticals have been published by the International Commission on Radiological Protection (ICRP) and the MIRD Committee but without information concerning uncertainties. The uncertainty information of dose coefficients is important, for example, to compare alternative diagnostic methods and choose the method that causes the lowest patient exposure with appropriate and comparable diagnostic quality. For the study presented here, an uncertainty analysis method was developed and used to calculate the uncertainty of the internal doses of 7 common radiopharmaceuticals. Methods: On the basis of the generalized schema of dose calculation recommended by the ICRP and MIRD Committee, an analysis based on propagation of uncertainty was developed and applied for 7 radiopharmaceuticals. The method takes into account the uncertainties contributed from pharmacokinetic models and the so-called S values derived from several voxel computational phantoms previously developed at Helmholtz Zentrum München. Random and Latin hypercube sampling techniques were used to sample parameters of pharmacokinetic models and S values, and the uncertainties of absorbed doses and effective doses were calculated. Results: The uncertainty factors (square root of the ratio between 97.5th and 2.5th percentiles) for organabsorbed doses are in the range of 1.1-3.3. Uncertainty values of effective doses are lower in comparison to absorbed doses, the maximum value being approximately 1.4. The ICRP reference values showed a deviation comparable to the effective dose calculated in this study. Conclusion: A general statistical method was developed for calculating the uncertainty of absorbed doses and effective doses for 7 radiopharmaceuticals. The dose uncertainties can be used to further identify the most important parameters in the dose calculation and provide reliable dose coefficients for risk analysis of the patients in nuclear medicine.

Internal dosimetry after incorporation of radionuclides requires standardized biokinetic and dosimetric models. The aim of the present work was to identify the parameters and the components of the models which contribute most to dosimetric uncertainty. For this a method was developed allowing for the calculation of the uncertainties of the absorbed dose coefficients. More specifically, the sampling-based regression method and the variance-based method were used to develop and apply a global method of sensitivity analysis. This method was then used to quantify the impact of various biokinetic and dosimetric parameters on the uncertainty of internal doses associated with the incorporation of seven common radiopharmaceuticals. It turned out that the correlation between biokinetic parameters and time-integrated activity or calculated absorbed dose is strongest when the source and target organ are identical, in accordance with the ICRP and the MIRD approach. According to the ICRP approach, the parameter F which describes the fractional distribution of any incorporated radioactivity to organ S, has the greatest correlation with the time-integrated activity in the corresponding source organ or with the calculated dose in the corresponding target organ. In contrast, the MIRD approach suggested several biokinetic parameters with similar correlation. The dosimetric parameters usually contribute more to uncertainty in the calculated dose coefficients than the biokinetic parameters, in both approaches. The results obtained are helpful for the revision of biokinetic models for radiopharmaceuticals, because the most important parameters in clinical applications can now be identified and investigated in future studies.

This article presents nuclide-specific organ dose rate coefficients for environmental external exposures due to soil contamination assumed as a planar source at a depth of 0.5 g cm−2 in the soil and submersion to contaminated air, for a pregnant female and its fetus at the 24th week of gestation. Furthermore, air kerma free-in-air coefficient rates are listed. The coefficients relate the organ equivalent dose rates (Sv s−1) to the activity concentration of environmental sources, in Bq m−2 or Bq m−3, allowing to time-integrate over a particular exposure period. The environmental radiation fields were simulated with the Monte Carlo radiation transport codes PHITS and YURI. Monoenergetic organ dose rate coefficients were calculated employing the Monte Carlo code EGSnrc simulating the photon transport in the voxel phantom of a pregnant female and fetus. Photons of initial energies of 0.015–10 MeV were considered including bremsstrahlung. By folding the monoenergetic dose coefficients with the nuclide decay data, nuclide-specific organ doses were obtained. The results of this work can be employed for estimating the doses from external exposures to pregnant women and their fetus, until more precise data are available which include coefficients obtained for phantoms at different stages of pregnancy.

Double tracer studies in healthy human volunteers with stable isotopes of cerium citrate were performed with the aim of investigating the gastro-intestinal absorption of cerium (Ce), its plasma clearance and urinary excretion. In the present work, results of the clearance of Ce in blood plasma are shown after simultaneous intravenous and oral administration of a Ce tracer. Inductively coupled plasma mass spectrometry was used to determine the tracer concentrations in plasma. The results show that about 80% of the injected Ce citrate cleared from the plasma within the five minutes postadministration. The data obtained are compared to a revised biokinetic model of cerium, which was initially developed by the International Commission on Radiological Protection (ICRP). The measured plasma clearance of Ce citrate was mostly consistent with that predicted by the ICRP biokinetic model. Furthermore, in an effort to quantify the uncertainty of the model prediction, the laboratory animal data on which the ICRP biokinetic Ce model is based, was analyzed. The measured plasma clearance and its uncertainty was also compared to the plasma clearance uncertainty predicted by the model. It was found that the measured plasma clearance during the first 15 minutes after administration is in a good agreement with the modelled plasma clearance. In general, the measured clearance falls inside the 95% confidence interval predicted by the biokinetic model.